Tech Company Inital Public Offerings
Castle Biosciences IPO
On 7/25/2019, Castle Biosciences went public.
Transaction Overview
Company Name
Announced On
7/25/2019
Transaction Type
IPO
Amount
$64,000,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows: approximately $17 million for selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of our current products and future products; approximately $17 million for research and development related to the continued support of our current products as well as the development of our product pipeline; and the remainder for working capital and other general corporate purposes, including the additional costs associated with being a public company.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3737 N. 7th St. 160
Phoenix, AZ 85014
USA
Phoenix, AZ 85014
USA
Phone
Website
Email Address
Overview
Castle Biosciences (Nasdaq: CSTL) offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Derek Maetzold
Chief Financial Officer
Frank Stokes
Chief Medical Officer
Federico Monzon
Chief Operating Officer
Bernhard Spiess
VP - Operations
Kristen Oelschlager
VP - R & D
Robert Cook
VP - Sales
Toby Juvenal
Browse more venture capital transactions:
Prev: 7/25/2019: Hippo venture capital transaction
Next: 7/26/2019: Intelligence Node venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs